LipimetiX Development Overview
- Founded
-
2012
- Status
-
Private
- Latest Deal Type
-
Corporate
- Financing Rounds
-
2
LipimetiX Development General Information
Description
Developer of drugs for cholesterol-related diseases. The company focuses on the development of drugs for the treatment of refractory hypercholesterolemia, hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company's technology is based upon a platform of chimeric peptide mimetics of apolipoprotein E, a critical protein that directs cholesterol and triglyceride-rich lipoproteins to receptors on the liver.
Contact Information
Website
www.lipimetix.com
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Primary Office
- 5 Commonwealth Road
- Suite 2A
- Natick, MA 01760
- United States
+1 (508) 000-0000
LipimetiX Development Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
LipimetiX Development Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Dennis Goldberg Ph.D | President, Chairman & Co-Founder | ||
| Philip Friden Ph.D | Vice President, Research & Development & Co-Founder |
LipimetiX Development Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|